drugset / Trial / NCT04779645
Effects of GRA in Patients With Type 1
Phase 2
Active not recruiting
30 enrolled
University of California, San Diego
REMD Biotherapeutics, Inc. · collab
RandomizedParallel-groupQuadruple-blindBasic science
Summary
This study will examine the effects a Glucagon Receptor Antagonist (GRA), has on Insulin Sensitivity, Cardiovascular risks (CVD), and Ketone body formation in participants with Type 1 diabetes. The participants will complete blood tests, tests to measure energy expenditure, CVD risks, and insulin resistance. These tests will be performed prior to start of treatment and again after 12-weeks of treatment with the GRA (called REMD-477).
Timeline
- Start
- 2021-07-31
- Primary completion
- 2024-07-17
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Volagidemab | Monoclonal antibody | 70 mg | Subcutaneous |